

## Announcement of full-year financial results 2009/10

(September 1, 2009 - August 31, 2010)

“In the financial year 2009/10 we continued to deliver profitable growth across all our business areas and sales regions. This positive development is clear evidence of our resilient and scalable business model. 2010/11 has started positively and we have set ambitious targets for this and for the coming years,” says CEO Lars Frederiksen.

### Highlights:

- Revenue amounted to EUR 576 million, up 13% over the previous year, corresponding to organic growth of 12%
- For Q4, revenue increased by 17% compared to the same period last year. Organic growth was 11%
- Operating profit (EBIT) margin before special items was 25%, compared to 22% the previous year. Revenue and operating profit growth is in accordance with the expectations most recently stated in the Company Announcement published on July 1 2010
- For Q4 the operating profit (EBIT) margin before special items was 28%, compared to 27% the previous year
- Dividend of DKK 0.64 per share equivalent to a payout ratio of 35%, adjusted for a capital contribution from Financière Star 1 to cover the net impact of an extraordinary bonus to all employees

### Outlook for 2010/11

- Revenue is expected to grow organically by 8-10%
- Operating profit (EBIT) margin is expected to be above 25%
- Net debt to EBITDA ratio is expected to be approximately 2.0 at year end

#### Conference call

Chr. Hansen will host a conference call on November 2, at 9:30 am CET. The conference call can be viewed at our home page [www.chr-hansen.com](http://www.chr-hansen.com).

#### Annual Report 2009/10

The Annual Report 2009/10 is attached to this company announcement

## Financial highlights and key ratios


This Annual Account Release is prepared in accordance with the recognition and measurement requirements of IFRS as endorsed by the EU, and with additional Danish disclosure requirements for listed companies.

EUR million	Q4 2009/10	Q4 2008/09	Full year 2009/10	Full year 2008/09	Full year growth %
<b>Income statement</b>					
Revenue	160.2	136.5	575.5	511.2	13%
Gross profit	79.7	67.6	285.1	242.1	18%
EBITDA b.s.i.	56.2	48.0	186.1	154.9	20%
Operating profit (EBIT) b.s.i.	44.9	36.8	143.3	113.9	26%
Operating profit (EBIT)	43.3	37.5	119.1	109.4	9%
Net profit	27.4	18.2	19.2	(18.4)	Neg.
<b>Cash Flow</b>					
Cash flow from operating activities	46.1	56.0	101.5	105.0	-3%
Cash flow from investing activities	(12.8)	(9.0)	(38.6)	(26.6)	45%
Free cash flow	33.3	47.0	62.9	78.4	-20%
<b>Financial position</b>					
Total assets	1,316.3	1,278.6	1,316.3	1,278.6	3%
Equity, excl. minorities	542.0	91.0	542.0	91.0	496%
Net working capital	93.6	77.8	93.6	77.8	20%
Net interest-bearing debt	474.5	814.7	474.5	814.7	-42%
<b>Earnings per share</b>					
EPS, continuing activities, diluted	0.20	0.18	0.17	(0.17)	
EPS, discontinued activities, diluted	0.00	0.00	(0.01)	(0.02)	
<b>Key figures</b>					
Organic revenue growth %	11%	11%	12%	10%	
Gross margin %	50%	50%	50%	47%	
EBITDA b.s.i. margin %	35%	35%	32%	30%	
Operating profit (EBIT) b.s.i. margin %	28%	27%	25%	22%	
Operating profit (EBIT) margin %	27%	27%	21%	21%	
ROIC % - excluding goodwill	32%	28%	27%	21%	
R&D %	-	-	6%	6%	
Capital expenditure %	-	-	7%	5%	
Debt to EBITDA	-	-	2.5	5.3	


## Management's review



Revenue, divisional split



Revenue, geographical split



Revenue amounted to EUR 576 million, up 13% over the previous year, corresponding to organic growth of 12%. All divisions and geographical regions contributed to the strong growth. The growth rate was positively impacted by a significant increase in prices of carmine color raw material, resulting in an increase of sales prices as well. This development enhanced the total revenue growth by approximately 2 percentage points.

For Q4, revenue amounted to EUR 160 million, an increase of 17% compared to the same period last year. Organic growth was 11%. The organic growth was positively affected by approximately 4.5 percentage points from higher raw material prices for carmine with corresponding increase in sales prices, but negatively affected by approximately 2.5 percentage points due to appreciation of currencies in countries where we today price based on euro price lists.

The Cultures & Enzymes Division accounted for 62% of the total revenue in 2009/10, a revenue growth of 8%, corresponding to organic growth of 6%. The Health & Nutrition Division experienced organic growth of 14% and revenue growth of 15% and accounted for 14% of the Group revenue. Revenue in the Colors & Blends Division grew by 26%, corresponding to organic growth of 29%, primarily driven by the sales of natural colors. The Colors & Blends Division contributed 24% of the total revenue.

Our Sales operations are divided into four regions, Europe, North America, South America, and Asia-Pacific, Middle East & Africa (APMEA). The European region accounted for 53% of the total revenue in 2009/10, a revenue growth rate of 7%, corresponding to organic growth of 10%.

Natural colors, human health products and fermented milk cultures performed strongly, while sales of coagulants to the cheese segment declined slightly. The North American region contributed 21% of the total revenue, a revenue growth rate of 10%, equivalent to organic growth of 10%. The region experienced good growth rates in all product areas except for animal health products, where sales of silage cultures were negatively affected by de-stocking at certain customers and a generally difficult economic environment in the agricultural industry. Revenue in the South American region grew by 23%, corresponding to 14% organic growth, driven primarily by dairy products and natural color solutions. Revenue in South America accounted for 11% of the total revenue. Revenue growth in the APMEA region was driven by human health products, dairy cultures and natural color solutions. The region contributed 15% of the total revenue, a revenue growth rate of 31%, equal to 24% organic growth.

### **Gross profit**

The gross profit increased by 18% over last year to EUR 285 million, representing an improvement in the gross profit margin of 3 percentage points, despite a less profitable business mix. The positive development was mainly a result of increased production efficiency, primarily driven by the culture plant in Copenhagen.

### **Costs**

Costs totalled EUR 142 million compared to EUR 128 million last year, an increase of 11%. Beyond inflation, the increase relates mainly to a strengthening of the sales and marketing organization as well as research and development activities. Administration expenses increased primarily due to higher costs resulting from our listed company status.

Capitalized development costs amounted to EUR 11 million, an increase of EUR 1 million over last year. The increase, combined with enhanced efficiency in the Research & Development team, improved our ability to launch new solutions for our customers and introduce better production methods. The total research and development expenses excluding an amortization of EUR 2 million amounted to EUR 33 million, corresponding to 6% of total revenue, which is at the same level as last year. The primary focus of the development activities is support of the Cultures & Enzymes Division and the Health & Nutrition Division, where research and development costs correspond to 6% and 10% of revenue, respectively. Significant research and development projects undertaken are Yo-Flex<sup>®</sup> cultures developed for drinking yogurts, probiotics for weight management, ColorFruit<sup>®</sup> Orange and a range of new encapsulated colors.

### **Special items**

Special items amounted to EUR 24 million, of which EUR 18 million relate to an extraordinary bonus to all employees. The expense net of tax has been reimbursed by the majority shareholder Financière Star 1 through a capital contribution. As a result, the operating profit (EBIT) was negatively impacted by the bonus payment, even though the cash flow effect was neutral for Chr. Hansen.

### **Operating profit (EBIT)**

The operating profit (EBIT) amounted to EUR 119 million. Operating profit (EBIT) margin came to 21%, the same level as last year. The EBIT margin before special items was 25%, compared to

22% the previous year. All divisions demonstrated scalability with increasing margins.

The operating profit (EBIT) for Q4 amounted to EUR 43 million while operating profit (EBIT) margin was 27%.

#### **Net financials and tax**

Net financial expenses amounted to EUR 67 million of which EUR 60 million was net interest expenses, EUR 8 million was negative net exchange rate adjustments and EUR 12 million was amortized costs related to the previous credit facilities, which were expensed as a consequence of the refinancing of long-term debt in June 2010 in connection with the IPO. The net gain related to derivative financial instruments was EUR 16 million. As a result of the refinancing in June 2010, net interest expenses for Q4 decreased.

Corporation tax amounted to EUR 32 million which comprises EUR 46 million in tax on operating profit net of tax on financial expenses. This corresponds to an effective tax rate of 38%. The tax rate was negatively influenced by adjustments related to potential tax liabilities.

#### **Profit/Loss for the period**

Net profit for the year amounted to EUR 19 million, compared to last year's loss of EUR 18 million. Net profit for Q4 amounted to EUR 27 million compared to a profit of EUR 18 million in Q4 last year.

#### **Assets**

At August 31, 2010, total assets amounted to EUR 1,316 million, which was EUR 38 million higher than last year-end. The increase in non-current assets amounted to EUR 20 million, primarily due to currency translations of assets in foreign group enterprises and capital expenditure.

Total current assets amounted to EUR 240 million, compared to EUR 222 million at August 31, 2009. Inventories increased by EUR 19 million to EUR 75 million, primarily due to increased raw material prices as well as increased revenue, while cash and cash equivalents decreased by EUR 19 million to EUR 61 million. Trade receivables increased by EUR 12 million to EUR 83 million driven mainly by higher sales activity.

Net working capital at August 31, 2010 amounted to EUR 94 million corresponding to 16% of revenue and representing an increase of EUR 16 million from EUR 78 million. Improvement of the net working capital position remains a constant focus area for Chr. Hansen.

#### **Equity**

On June 3, 2010, Chr. Hansen Holding A/S was successfully launched on the NASDAQ OMX Copenhagen. The net proceeds from the listing amounted to EUR 431 million; new shares issued generated EUR 450 million and the company's share of the IPO costs amounted to EUR 19 million. In order to cover the new share-based incentive programs, treasury shares worth EUR 35 million were purchased. Total equity at year end amounted to EUR 546 million, compared to EUR 94 million at last year-end.

### **Proposed dividend**

At the Annual General Meeting on November 30, 2010, the Board of Directors will propose a dividend of DKK 0.64 per share of DKK 10 corresponding to a payout ratio of 35%, adjusted for the capital contribution from Financière Star 1. The total dividend payment is expected to amount to EUR 12 million.

### **Holding of treasury shares**

As per August 31, 2010, Chr. Hansen Holding A/S holds 2,894,034 shares corresponding to 2% of the total share capital. The shares were purchased as part of the IPO in order to cover the new share-based incentive programs.

### **Net debt**

In June 2010, the company's long-term debt was refinanced. The net proceeds from the sale of new shares at the IPO were used to repay part of the long-term debt and the remaining debt was refinanced. The effect of the refinancing was a deleveraging and longer maturity on the remaining debt. The improved debt structure gives Chr. Hansen the ability to pursue future growth opportunities and mitigates the negative tax impact from the Danish interest ceiling rules. Net interest-bearing debt amounted to EUR 475 million on August 31, 2010, which represents 2.5 times EBITDA before special items. At August 31, 2009 the net interest bearing debt was EUR 815 million. At year end approximately 53% of the debt was secured at fixed interest rates. The total debt has an average maturity of 4.7 years.

### **Cash flow**

Cash flow from operating activities amounted to EUR 102 million compared to last year's EUR 105 million. The decrease was mainly due to an increase in inventory partly compensated for by an increase in operating profit. The operating profit for the year was EUR 119 million, an increase of EUR 10 million compared to last year. The operating profit for the year was negatively impacted by the extraordinary bonus of EUR 18 million, reimbursed by the majority shareholder, Financière Star 1, through a capital contribution.

Cash flow from investing activities amounted to EUR 39 million, compared to EUR 27 million last year. Investment in property, production plants and equipment amounted to EUR 19 million whereas capitalized development projects amounted to EUR 11 million during the period.

Free cash flow amounted to EUR 63 million, compared to EUR 78 million last year. In 2008/09, the free cash flow was positively impacted by a relatively low investment level with primary focus on the start-up of the new culture plant in Copenhagen.

Cash flow from financing activities amounted to EUR 86 million and was heavily influenced by the IPO and refinancing of long-term debt. Net proceeds from the IPO in June amounted to EUR 431 million. In the refinancing, the repayment of long-term debt amounted to EUR 947 million, including the voluntary repayment in December 2009 of EUR 26 million and repayment of shareholder loan. New loans contributed EUR 450 million.

At year-end, cash and cash equivalents amounted to EUR 61 million.

## Segment information

### Cultures & Enzymes Division

EUR million	Q4 2009/10	Q4 2008/09	Full year 2009/10	Full year 2008/09
Revenue	96.6	89.4	356.2	331.1
Organic growth	2%	9%	6%	9%
EBITDA	41.6	37.0	137.7	116.7
EBITDA margin	43%	41%	39%	35%
Operating profit (EBIT)	33.1	28.1	104.3	84.6
Operating profit (EBIT) margin	34%	31%	29%	26%

For 2009/10 revenue in the Cultures & Enzymes Division increased by 8% to EUR 356 million, corresponding to an organic revenue growth of 6%.

The growth in 2009/10 was largely driven by increased sales of cultures for fermented milk and probiotic products combined with ongoing efforts to strengthen our sales platform in the emerging markets, particularly in Asia and South America. Growth in yogurt consumption in the North American market also affected the division positively. The growth in sales of enzymes was negatively affected by our decision to reduce sales of contract-manufactured animal rennet as well as by price decreases related to lower raw material prices for animal rennet.

In Q4, organic growth was 2% compared to the same period last year. The lower organic growth rate was negatively affected by appreciation of currencies in countries where we today price based on euro pricelist by approximately 2.5 percentage point, and by timing of large orders in the APMEA region last year by approximately 1.5 percentage point. In addition to this, the uncertainty surrounding EFSA/EU regulations of health claims had some negative effect on the historically high growth rates of probiotic culture sales.

Operating profit (EBIT) margin increased to 29%, compared with 26% last year driven by revenue growth, favorable product mix and production efficiencies.

In Q4 operating profit (EBIT) margin was 34% compared to 31% in the same period last year.

## Health & Nutrition Division

EUR million	Q4 2009/10	Q4 2008/09	Full year 2009/10	Full year 2008/09
Revenue	20.3	19.1	78.8	68.6
Organic growth	2%	29%	14%	27%
EBITDA	8.6	7.7	27.8	23.9
EBITDA margin	42%	40%	35%	35%
Operating profit (EBIT)	7.2	6.5	23.2	19.7
Operating profit (EBIT) margin	35%	34%	29%	29%

In 2009/10 revenue in the Health & Nutrition Division increased by 15% to EUR 79 million. Organic growth of 14% was driven by the human health area, while animal health contracted.

The growth in the human health area was mainly driven by the general market recovery following the financial crisis, particularly in Eastern Europe, continued market growth in Asia-Pacific, Middle East & Africa and North America.

The animal health area was negatively impacted by decreased sales of cultures for silage inoculation due to inventory reduction at certain customers and a generally difficult economic situation for the agricultural industry. Sales of probiotic cultures within animal health experienced growth throughout the year especially driven by South and North America and dedicated focus within the poultry segment.

In Q4 revenue for the Health and Nutrition Division increased to EUR 20 million corresponding to organic growth of 2%. The growth was negatively affected by the decreased sales of cultures for silage inoculation, whereas probiotic cultures for animals continued to grow. Growth within human health was lower than in the first three quarters due to timing of certain large orders, but was still double digit.

Despite higher costs for research & development and sales & marketing, operating profit (EBIT) increased by 18%, primarily driven by the increased sales volumes. The operating profit (EBIT) margin reached 29%, the same level as last year.

In Q4 operating profit (EBIT) margin was 35% compared to 34% in the same period last year.



## Colors & Blends Division

EUR million	Q4 2009/10	Q4 2008/09	Full year 2009/10	Full year 2008/09
Revenue	43.3	28.0	140.5	111.5
Organic growth	45%	7%	29%	6%
EBITDA	6.0	3.3	20.6	14.3
EBITDA margin	14%	12%	15%	13%
Operating profit (EBIT)	4.6	2.3	15.8	9.6
Operating profit (EBIT) margin	11%	8%	11%	9%

In 2009/10 revenue for the Colors & Blends Division increased by 26% to EUR 141 million. Organic growth was 29% driven by the continued conversion trend of replacing synthetic colors with natural colors. Increasing raw material prices for carmine colors affected the organic growth positively by approximately 8 percentage points.

In Q4, organic growth was 45% driven by continued high demand, while higher raw material prices for carmine colors affected the growth positively by approximately 22 percentage points.

Operating profit (EBIT) increased by 65% to EUR 16 million, while operating profit (EBIT) margin increased from 9% last year to 11% in 2009/10. The increase was driven by the higher sales activity, but partly offset by the negative effect of the significant increase in raw material prices for carmine colors. Overall, the increase in raw material prices has been reflected in sales prices securing absolute earnings, but still impacting margins negatively.

Operating profit (EBIT) margin in Q4 was 11% compared to 8% in the same period last year, despite impact from the above mentioned increase in raw material prices.

## Outlook

Chr. Hansen's revenue growth is driven by four fundamental factors:

- Growth in the size of global middle income groups leading to increased demand for healthy food products
- Conversion i.e. from in-house bulk starter to DVS<sup>®</sup> cultures and from synthetic to natural colors
- Added functionality in food, i.e. probiotics
- Market share gains

Due to the scalability of our business model, driven by our global commercial footprint and our efficient production platform, operating profit (EBIT) is expected to grow faster than revenue.

### Long term ambition (3-5 years)

Based on the fundamental growth factors, annual revenue is expected to grow organically in the region of 8-10%. Operating profit (EBIT) margin before special items is expected to increase gradually, assuming an unchanged business mix. Net working capital (NWC) is expected to be 14 -17% of revenue and capital expenditure at 6.5-7.5% of revenue.

Research & development expenditure (costs and capitalization) excluding amortization is expected to be around 6% of revenue.

Consequently a high cash conversion is expected and net debt leverage is expected to be between 2-2.5 times EBITDA with excess capital distributed to the shareholders.

### 2010/11 outlook

The financial year 2010/11 has started positively and organic revenue growth for the full year is expected to be 8-10%. Operating profit (EBIT) margin is expected to be above 25%. The tax rate is estimated to be around 26%.

As a result of healthy cash conversion, and key ratios in line with the long term targets, net debt to EBITDA ratio is expected to decrease to approximately 2.0 times from 2.5 at the end of the 2009/10 financial year.

The above outlook is based on the assumption that due to the increased raw material prices for carmine during 2009/10, the organic growth for the Colors & Blends Division will decline in the second half of 2010/11 compared to the first half of the financial year.

The long term targets and 2010/11 outlook are sensitive to major changes in the global economy including the USD exchange rate, which could impact the operational and financial performance of the company.

## Management statement

The Board of Directors and Executive Management today considered and approved the audited Consolidated Financial Statements in the Annual Report of Chr. Hansen Holding A/S for the financial year ended August 31, 2010.

The Board of Directors and Executive Management also approved this unaudited Annual Account Release containing financial information for Q4 2009/10 and condensed financial information for the financial year ended August 31, 2010.

The Consolidated Financial Statements in the Annual Report have been prepared in accordance with the International Financial Reporting Standards as adopted by the EU. In addition, the Annual Report has been presented in accordance with additional Danish disclosure requirements for listed companies. We consider the accounting policies used to be appropriate and the accounting estimates reasonable, and in our opinion, the Consolidated Financial Statements in the Annual Report give a true and fair view of the Group's assets, liabilities and financial position at August 31, 2010 and of the results of the Group's operations and cash flows.

This Annual Account Release has been prepared in accordance with the accounting policies as applied in the Consolidated Financial Statements for the financial year ended August 31, 2010 and additional Danish disclosure requirements for listed companies, and in our opinion the overall presentation of this Annual Account Release is adequate.

We further consider that the Management's Review in the preceding pages includes a true and fair account of the development and performance of the Group, the results for the year and of the financial position, together with a description of the principal risks and uncertainties that the Group faces in accordance with Danish disclosure requirements for listed companies.

Hoersholm, November 2, 2010

### Executive Board

Lars Frederiksen  
*President and CEO*

Henning Jakobsen  
*Chief Financial Officer*

Knud Vindfeldt  
*Executive Vice President*

Henrik Dalboege  
*Executive Vice President*

Carsten Hellmann  
*Executive Vice President*

### Board of Directors

Ole Andersen  
*Chairman*

Frédéric Stévenin  
*Vice Chairman*

Henrik Poulsen

Alice Dautry

Lionel Zinsou

Gaëlle d'Engremont

Joergen O. Nielsen

Svend Laulund

Martin G. Seidel

## Other information

### Annual General Meeting

The Annual General Meeting will be held in Radisson Blu, Frederiksberg on Tuesday November 30, 2010 at 4.00 p.m.

The Annual Report is available at [www.chr-hansen.com](http://www.chr-hansen.com). The printed version of the Annual Report is expected to be available on November 18, and will be distributed to shareholders on request.

### For further information, please contact:

Lars Frederiksen, CEO

Tel: +45 45 74 74 74

Anders Mohr Christensen, Investor Relations

Tel: +45 45 74 76 18

## Financial Calendar

### 2010

30 November Annual General Meeting

### 2011

12 January Interim Report (Q1 2010/11)

6 April Interim Report (Q2 2010/11)

6 July Interim Report (Q3 2010/11)

3 November Annual Report 2010/11

29 November Annual General Meeting

## Forward-looking statements

This annual report contains forward-looking statements. Such statements are subject to risks and uncertainties as various factors, many of which are beyond the control of Chr. Hansen Holding A/S, may cause actual developments and results to differ materially from the expectations expressed in the annual report.

## Governing text

The annual report has been translated from Danish. The Danish text shall govern for all purposes and prevail in the event of any discrepancy between the versions.

## About Chr. Hansen

Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. The products are centered around cultures, enzymes, probiotics and natural colors, and all solutions are based on strong research and development competencies coupled with significant technology investments. Revenue in the 2009/10 financial year was EUR 576 million. The company holds a leading market position in all its divisions: Cultures & Enzymes, Health & Nutrition and Colors & Blends. It has more than 2,300 dedicated employees in over 30 countries. Chr. Hansen was founded in 1874 and is today listed on NASDAQ OMX Copenhagen. For further information, please visit [www.chr-hansen.com](http://www.chr-hansen.com).

## INCOME STATEMENT SEPTEMBER 1 - AUGUST 31

EUR millions	Q4 2009/10	Q4 2008/09	FY 2009/10	FY 2008/09
<b>Revenue</b>	160.2	136.5	575.5	511.2
Cost of sales	(80.3)	(68.9)	(290.4)	(269.1)
<b>Gross profit</b>	<b>79.9</b>	<b>67.6</b>	<b>285.1</b>	<b>242.1</b>
Expenses	(35.0)	(30.8)	(141.8)	(128.2)
<b>Operating profit before special items</b>	<b>44.9</b>	<b>36.8</b>	<b>143.3</b>	<b>113.9</b>
Special items	(1.6)	0.7	(24.2)	(4.5)
<b>Operating profit</b>	<b>43.3</b>	<b>37.5</b>	<b>119.1</b>	<b>109.4</b>
Net financial expenses	(4.8)	(10.1)	(67.0)	(106.5)
<b>Profit/Loss before tax</b>	<b>38.5</b>	<b>27.4</b>	<b>52.1</b>	<b>2.9</b>
Corporation tax	(11.0)	(9.4)	(32.4)	(18.9)
<b>Profit/Loss from continuing activities</b>	<b>27.5</b>	<b>18.0</b>	<b>19.7</b>	<b>(16.0)</b>
Loss from discontinued activities	(0.1)	0.2	(0.5)	(2.4)
<b>Profit/Loss for the period</b>	<b>27.4</b>	<b>18.2</b>	<b>19.2</b>	<b>(18.4)</b>
Distributed on:				
Minority interests	0.4	0.1	1.4	1.1
<b>Shareholder of Chr. Hansen Holding A/S</b>	<b>27.0</b>	<b>18.1</b>	<b>17.8</b>	<b>(19.5)</b>
<b>Earnings per share, EUR:</b>				
Earnings per share, continuing activities	0.20	0.18	0.17	(0.17)
Earnings per share, continuing activities, diluted	0.20	0.18	0.17	(0.17)
Earnings per share, discontinued activities	(0.00)	0.00	(0.01)	(0.02)
Earnings per share, discontinued activities, diluted	(0.00)	0.00	(0.01)	(0.02)

## STATEMENT OF COMPREHENSIVE INCOME SEPTEMBER 1 - AUGUST 31

EUR millions	Q4 2009/10	Q4 2008/09	FY 2009/10	FY 2008/09
<b>Profit/Loss for the period</b>	<b>27.4</b>	<b>18.2</b>	<b>19.2</b>	<b>(18.4)</b>
Currency translation of foreign group enterprises	(4.4)	2.2	21.4	(12.1)
Cash flow hedge	(1.5)	-	(1.5)	-
Tax related to cash flow hedge	0.3	-	0.3	-
<b>Other comprehensive income for the period</b>	<b>(5.6)</b>	<b>2.2</b>	<b>20.2</b>	<b>(12.1)</b>
<b>Total comprehensive income for the period</b>	<b>21.8</b>	<b>20.4</b>	<b>39.4</b>	<b>(30.5)</b>
Distributed on:				
Shareholder of Chr. Hansen Holding A/S	21.5	20.0	37.8	(31.0)
Minority interests	0.3	0.4	1.6	0.5
	<b>21.8</b>	<b>20.4</b>	<b>39.4</b>	<b>(30.5)</b>

## STATEMENT OF FINANCIAL POSITION

### Assets

EUR millions	Aug 31, 2010	Aug 31, 2009
<b>Non-current assets</b>		
<b>Intangible assets</b>		
Goodwill	625.6	603.4
Other intangible assets	155.1	163.4
Intangible assets in progress	35.1	21.4
	<b>815.8</b>	<b>788.2</b>
<b>Property, plant and equipment</b>		
Land and buildings	136.3	137.4
Plant and machinery	100.3	111.5
Other fixtures and equipment	6.9	6.0
Property, plant and equipment in progress	15.0	8.9
	<b>258.5</b>	<b>263.8</b>
<b>Other non-current assets</b>		
Deferred tax	2.2	4.8
	<b>2.2</b>	<b>4.8</b>
<b>Total non-current assets</b>	<b>1,076.5</b>	<b>1,056.8</b>
<b>Current assets</b>		
<b>Inventories</b>		
Raw materials and consumables	12.1	13.6
Work in progress	20.5	13.7
Finished goods and goods for resale	42.7	29.5
	<b>75.3</b>	<b>56.8</b>
<b>Receivables</b>		
Trade receivables	82.9	70.8
Tax receivable	6.7	2.4
Other receivables	8.2	6.7
Prepayments	5.7	4.3
	<b>103.5</b>	<b>84.2</b>
<b>Receivables regarding discontinued activities</b>	<b>-</b>	<b>0.5</b>
<b>Cash and cash equivalents</b>	<b>61.0</b>	<b>80.3</b>
<b>Total current assets</b>	<b>239.8</b>	<b>221.8</b>
<b>Total assets</b>	<b>1,316.3</b>	<b>1,278.6</b>

Announcement of full-year financial results 2009/10, Chr. Hansen Holding A/S

Page 15/18

Chr. Hansen Holding A/S  
Boege Allé 10-12  
DK-2970, Hoersholm  
Denmark

Tel. +45 45 74 74 74  
www.chr-hansen.com  
CVR-no: 28318677

## STATEMENT OF FINANCIAL POSITION

### Equity and liabilities

EUR millions	Aug 31, 2010	Aug 31, 2009
<b>Equity</b>		
Share capital	185.4	135.5
Reserves	356.6	(44.5)
Minority interests	3.7	2.8
<b>Total equity</b>	<b>545.7</b>	<b>93.8</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
Employee benefit obligations	5.4	5.6
Deferred tax	71.3	66.6
Provisions	2.8	0.9
Borrowings	523.9	856.8
Payable to Parent Company	-	87.0
Corporation tax	8.9	14.1
Other non-current debt	2.3	2.6
	<b>614.6</b>	<b>1,033.6</b>
<b>Current liabilities</b>		
Provisions	0.8	1.3
Borrowings	11.6	38.2
Payable to Parent Company	-	-
Prepayments from customers	0.2	0.1
Trade payables	64.6	49.8
Corporation tax	26.3	4.5
Other payables	52.5	57.3
	<b>156.0</b>	<b>151.2</b>
<b>Total liabilities</b>	<b>770.6</b>	<b>1,184.8</b>
<b>Total equity and liabilities</b>	<b>1,316.3</b>	<b>1,278.6</b>

Announcement of full-year financial results 2009/10, Chr. Hansen Holding A/S

Chr. Hansen Holding A/S  
Boege Allé 10-12  
DK-2970, Hoersholm  
Denmark

Tel. +45 45 74 74 74  
www.chr-hansen.com  
CVR-no: 28318677

Page 16/18



## STATEMENT OF CHANGES IN EQUITY

Sep 1, 2009 - Aug 31, 2010

Shareholder of Chr. Hansen Holding A/S								
EUR millions	Share capital	Treasury shares	Currency translation	Cash flow hedge	Retained earnings	Total	Minority interests	Total
<b>Balance September 1, 2009</b>	<b>135.5</b>	-	<b>(18.6)</b>	-	<b>(25.9)</b>	<b>91.0</b>	<b>2.8</b>	<b>93.8</b>
Capital increase	50.0	-	-	-	400.0	<b>450.0</b>	-	<b>450.0</b>
IPO-related cost	-	-	-	-	(18.6)	<b>(18.6)</b>	-	<b>(18.6)</b>
Capital contribution	-	-	-	-	15.6	<b>15.6</b>	-	<b>15.6</b>
Purchase of treasury shares	-	(35.0)	-	-	-	<b>(35.0)</b>	-	<b>(35.0)</b>
Total comprehensive income for the period, cf. Statement of comprehensive income	(0.1)	-	21.3	(1.2)	17.8	<b>37.8</b>	1.6	<b>39.4</b>
Share-based payment	-	-	-	-	1.2	<b>1.2</b>	-	<b>1.2</b>
Dividend	-	-	-	-	-	-	(0.7)	<b>(0.7)</b>
<b>Balance August 31, 2010</b>	<b>185.4</b>	<b>(35.0)</b>	<b>2.7</b>	<b>(1.2)</b>	<b>390.1</b>	<b>542.0</b>	<b>3.7</b>	<b>545.7</b>

Sep 1, 2008 - Aug 31, 2009

Shareholder of Chr. Hansen Holding A/S								
EUR millions	Share capital	Treasury shares	Currency translation	Cash flow hedge	Retained earnings	Total	Minority interests	Total
<b>Balance September 1, 2008</b>	<b>135.2</b>	-	<b>(6.8)</b>	-	<b>(6.6)</b>	<b>121.8</b>	<b>3.4</b>	<b>125.2</b>
Total comprehensive income for the period, cf. Statement of comprehensive income	0.3	-	(11.8)	-	(19.5)	<b>(31.0)</b>	0.5	<b>(30.5)</b>
Share-based payment	-	-	-	-	0.2	<b>0.2</b>	-	<b>0.2</b>
Dividend	-	-	-	-	-	-	(1.1)	<b>(1.1)</b>
<b>Balance August 31, 2009</b>	<b>135.5</b>	-	<b>(18.6)</b>	-	<b>(25.9)</b>	<b>91.0</b>	<b>2.8</b>	<b>93.8</b>

## STATEMENT OF CASH FLOWS SEPTEMBER 1 - AUGUST 31

EUR millions	Q4 2009/10	Q4 2008/09	FY 2009/10	FY 2008/09
<b>Operating profit</b>	<b>43.3</b>	<b>37.5</b>	<b>119.1</b>	<b>109.4</b>
Adjustments	13.0	12.8	44.5	42.8
Change in working capital	3.3	22.1	(9.3)	13.9
Interest payments received	5.6	2.2	5.9	2.9
Interest payments made	(14.0)	(9.1)	(45.7)	(48.5)
Cash flow from discontinued operations	(0.5)	(4.8)	(0.5)	(7.4)
Taxes paid	(4.6)	(4.7)	(12.5)	(8.1)
<b>Cash flow from operating activities</b>	<b>46.1</b>	<b>56.0</b>	<b>101.5</b>	<b>105.0</b>
Acquisition of entities	-	(0.2)	-	(4.6)
Discontinued and divested activities	0.4	-	-	5.5
Investments in intangible assets	(8.5)	(9.6)	(20.0)	(17.4)
Investments in property, plant and equipment	(5.0)	0.6	(18.9)	(11.1)
Sale of property, plant and equipment	0.3	0.2	0.3	1.0
<b>Cash flow from investing activities</b>	<b>(12.8)</b>	<b>(9.0)</b>	<b>(38.6)</b>	<b>(26.6)</b>
<b>Free cash flow</b>	<b>33.3</b>	<b>47.0</b>	<b>62.9</b>	<b>78.4</b>
Capital contribution	447.0	-	447.0	-
Raising of long-term loans	450.0	20.6	450.0	20.6
Repayment of long-term loans	(808.0)	(60.7)	(853.2)	(99.3)
Treasury shares	(35.0)	-	(35.0)	-
Repayment of shareholder loan	(93.6)	-	(93.6)	-
Minority interests, dividend etc.	(0.3)	(0.3)	(0.7)	(1.0)
<b>Cash flow from financing activities</b>	<b>(39.9)</b>	<b>(40.4)</b>	<b>(85.5)</b>	<b>(79.7)</b>
<b>Net cash flow for the periode</b>	<b>(6.6)</b>	<b>6.6</b>	<b>(22.6)</b>	<b>(1.3)</b>
Cash and cash equivalents at beginning of period	67.1	73.3	80.3	82.6
Unrealised exchange gain included in cash and cash equivalents	0.5	0.4	3.3	(1.0)
Net cash flow for the period	(6.6)	6.6	(22.6)	(1.3)
<b>Cash and cash equivalents at August 31</b>	<b>61.0</b>	<b>80.3</b>	<b>61.0</b>	<b>80.3</b>